ECO Animal Health Group (LON:EAH) Reaches New 1-Year High – Still a Buy?

Posted by Don Miller on Sep 29th, 2025

Shares of ECO Animal Health Group plc (LON:EAH – Get Free Report) reached a new 52-week high on Monday . The company traded as high as GBX 100 ($1.34) and last traded at GBX 96.31 ($1.29), with a volume of 280931 shares. The stock had previously closed at GBX 99.10 ($1.33).

Analyst Upgrades and Downgrades

Separately, Shore Capital reaffirmed a “buy” rating and issued a GBX 150 price objective on shares of ECO Animal Health Group in a report on Monday, July 14th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of GBX 150.

Check Out Our Latest Report on ECO Animal Health Group

ECO Animal Health Group Stock Down 2.8%

The stock’s 50-day moving average is GBX 77.15 and its 200-day moving average is GBX 66.14. The stock has a market cap of £65.00 million, a P/E ratio of 3,963.37 and a beta of -0.05. The company has a current ratio of 2.96, a quick ratio of 2.14 and a debt-to-equity ratio of 4.81.

ECO Animal Health Group (LON:EAH – Get Free Report) last announced its earnings results on Monday, July 14th. The company reported GBX 2.49 earnings per share (EPS) for the quarter. ECO Animal Health Group had a net margin of 1.17% and a return on equity of 1.27%.

Insider Buying and Selling at ECO Animal Health Group

In other ECO Animal Health Group news, insider David Hallas acquired 29,897 shares of ECO Animal Health Group stock in a transaction dated Tuesday, July 15th. The stock was bought at an average price of GBX 67 per share, for a total transaction of £20,030.99. Company insiders own 11.03% of the company’s stock.

About ECO Animal Health Group

(Get Free Report)

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.